What Is Trulicity Approved For? Label Indications, Per the Research

Trulicity is the brand name for dulaglutide, a prescription medicine given by injection. A 2014 review in Drugs described dulaglutide's first global approval, reporting that the once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist was approved in the USA for the treatment of adults with type 2 diabetes mellitus as an adjunct to diet and exercise (PMID 25367716). That approval is the anchor point for any discussion of what the medicine is labelled for, and it is the indication that the verified literature summarised on this page documents.

This page is for educational purposes only and is not medical advice; consult a licensed physician or other qualified prescriber about whether any medicine is appropriate, and rely on the current, official prescribing information for the authoritative list of approved indications in a given country.

The approved indication in the published record

The 2014 Drugs review of dulaglutide's first global approval reported that the agent is a long-acting GLP-1 receptor agonist developed for once-weekly subcutaneous administration and approved for adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control (PMID 25367716). Two features of that wording matter when readers compare label text with marketing language or with social-media claims:

• Population: the approval described in the review was for adults with type 2 diabetes mellitus (PMID 25367716).
• Context of use: the review described the indication as an adjunct to diet and exercise, not as a standalone intervention (PMID 25367716).

Labelling for medicines is revised over time as new trials are submitted to regulators, and national labels can differ. The verified citation set used here documents the 2014 first global approval; it does not document subsequent label revisions, and this page therefore does not assert any later indication. Anyone who needs the current indication list for a specific country should read the official prescribing information or ask the prescribing clinician.

Where dulaglutide sits in its drug class

Dulaglutide belongs to the GLP-1 receptor agonist class. A reference monograph on GLP-1 analogues described this group as injectable agents developed for the treatment of type 2 diabetes that mimic the actions of the incretin hormone GLP-1 (PMID 31643819). A 2021 state-of-the-art review in Molecular Metabolism summarised the class's role in type 2 diabetes management, including effects on glycaemic control and the pharmacological rationale behind incretin-based therapy (PMID 33068776).

A 2025 comprehensive review in Drug Design, Development and Therapy examined the pharmacokinetics and drug-drug interaction profiles of approved GLP-1 receptor agonists together with a dual GLP-1/GIP receptor agonist, and researchers reported that differences in half-life and absorption across the class underlie their differing administration schedules (PMID 40330819). Class membership, however, does not mean shared indications: each molecule carries its own label, granted on the strength of its own trial programme.

Approval snapshot

What is not an approved indication in this citation set

Separating approved indications from off-label or investigational uses is the single most important distinction on a page like this. An approved indication means a regulator reviewed a submitted trial package and authorised marketing for that use. An off-label use means a clinician prescribes an approved medicine for something outside the authorised wording. An investigational use means the question is still being studied and no authorisation exists for it.

Investigational directions in the wider class

A 2025 German-language review in Der Nervenarzt examined whether GLP-1 receptor agonists might represent a new pharmacological treatment option for psychiatric illnesses, and the authors framed this as an emerging research question rather than established practice (PMID 40042613). Nothing in that review constitutes an approved psychiatric indication for dulaglutide or any other agent in the class.

Pregnancy

A 2025 review in the American Journal of Obstetrics and Gynecology surveyed GLP-1 receptor agonist use in pregnancy and reported that human safety data in this setting remain limited, which is why the topic is discussed in the literature as an area of uncertainty rather than an authorised use (PMID 39181497). Pregnancy-related questions are clinical questions for an obstetric clinician and prescriber.

Other GLP-1 medicines carry their own separate approvals

Because several incretin-based medicines are discussed interchangeably in popular coverage, it is worth stating plainly that trial results for one molecule do not transfer to another molecule's label.

• Semaglutide: a 2018 systematic review and meta-analysis in Diabetes, Obesity and Metabolism evaluated semaglutide in type 2 diabetes mellitus and reported improvements in glycaemic endpoints relative to comparators (PMID 29756388). A separate 2022 review in Postgraduate Medicine summarised the STEP programme and reported weight-management outcomes for semaglutide in that trial series (PMID 36691309).
• Tirzepatide: a 2024 review in Drugs covered tirzepatide in type 2 diabetes, describing it as a dual GIP and GLP-1 receptor agonist and summarising its phase 3 evidence base (PMID 38388874). A 2023 review in the Journal of Obesity & Metabolic Syndrome similarly examined tirzepatide efficacy and safety across type 2 diabetes and obesity management (PMID 36750526).
• Retatrutide: a 2023 randomised, double-blind, placebo- and active-controlled phase 2 trial in The Lancet studied retatrutide, a GIP, GLP-1 and glucagon receptor agonist, in people with type 2 diabetes in the USA (PMID 37385280). Phase 2 status means the molecule was under investigation, not approved.

In short: evidence about semaglutide, tirzepatide or retatrutide says nothing about what Trulicity is labelled for. The only approval documented for dulaglutide in this citation set is the 2014 type 2 diabetes approval (PMID 25367716).

Adverse Events: What Studies Report

Approval does not imply the absence of adverse effects; labels carry warnings and precautions alongside indications. The 2021 state-of-the-art review of GLP-1 receptor agonists in type 2 diabetes discussed the tolerability profile of the class, with gastrointestinal complaints featuring prominently among reported effects (PMID 33068776). A 2025 article in The Laryngoscope reviewed otolaryngologic side effects associated with GLP-1 receptor agonists, and researchers catalogued head-and-neck-region complaints reported in users of the class (PMID 39936458).

Interaction potential is a related safety consideration. The 2025 pharmacokinetics review reported that delayed gastric emptying is a mechanism relevant to drug-drug interaction assessment for approved GLP-1 receptor agonists and a dual GLP-1/GIP agonist (PMID 40330819). The GLP-1 analogue monograph likewise discussed class-level safety considerations documented for these injectable agents (PMID 31643819). Individual risk assessment, contraindications and monitoring are matters for a prescribing clinician, not for a summary page.

How to read a label indication accurately

1. Check the exact wording. The 2014 review reported an indication for adults with type 2 diabetes mellitus as an adjunct to diet and exercise, the qualifiers are part of the indication (PMID 25367716).
2. Check the country. A first global approval in one jurisdiction does not mean identical wording elsewhere; the 2014 review described the initial USA approval specifically (PMID 25367716).
3. Check the date. Labels are amended; a 2014 record describes the position at that time (PMID 25367716).
4. Do not import class data. Reviews of semaglutide or tirzepatide describe those molecules' evidence, not dulaglutide's label (PMID 29756388; PMID 38388874).

Questions a reader might bring to a clinician

• Which indication, in the current local prescribing information, applies to a given clinical situation?
• How do the gastrointestinal and other adverse effects described for the class in published reviews apply to an individual's history (PMID 33068776; PMID 39936458)?
• Do any current medicines raise the interaction considerations described in pharmacokinetic reviews of the class (PMID 40330819)?
• What do the published pregnancy data gaps mean for someone who is pregnant or planning pregnancy (PMID 39181497)?

Every use, suitability and continuation question belongs with a licensed prescriber who can see the full clinical picture. This page summarises what the cited literature reported and does not recommend, direct or endorse any course of action.

References

• Dulaglutide: first global approval (Drugs, 2014)
• GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art (Molecular Metabolism, 2021)
• Glucagon-Like Peptide-1 (GLP-1) Analogues (2012)
• A Comprehensive Review on the Pharmacokinetics and Drug-Drug Interactions of Approved GLP-1 Receptor Agonists and a Dual GLP-1/GIP Receptor Agonist (Drug Design, Development and Therapy, 2025)
• Otolaryngologic Side Effects of GLP-1 Receptor Agonists (The Laryngoscope, 2025)
• Glucagon-like peptide-1 receptor agonist use in pregnancy: a review (American Journal of Obstetrics and Gynecology, 2025)
• Glucagon-like peptide-1 receptor agonists: a new pharmacological treatment option for psychiatric illnesses? (Der Nervenarzt, 2025)
• Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis (Diabetes, Obesity & Metabolism, 2018)
• Efficacy and safety of semaglutide for weight management: evidence from the STEP program (Postgraduate Medicine, 2022)
• Tirzepatide: A Review in Type 2 Diabetes (Drugs, 2024)
• Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management (Journal of Obesity & Metabolic Syndrome, 2023)
• Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA (The Lancet, 2023)